Introduction {#Sec1}
============

Traumatic brain injury (TBI) is brain damage caused by external force. It is the main cause of death and disability among trauma patients \[[@CR1]\]. It is estimated that 53,000 people die each year from TBI in the United States and more than 5.3 million Americans are currently disabled for TBI \[[@CR2]\]. Patients who have undergone TBI often suffer from profound suppression of the cellular immune system and impaired consciousness \[[@CR3]\], and they usually require tracheal intubation and ventilator support \[[@CR4]\], both of which increased the incidence of ventilator-associated pneumonia (VAP).

VAP is a type of nosocomial pneumonia developing 48 h or more after receiving mechanical ventilation. Studies have shown that VAP can lead to increased mortality and morbidity \[[@CR5]\]. In addition, when patients suffered from VAP, the medical expenses increase \[[@CR6]\].

The incidence of VAP among patients with TBI reported in studies varies widely, ranging from 23 to 60% \[[@CR7]--[@CR9]\]. In addition, previous studies have demonstrated that the risk factors for VAP among patients with TBI include smoking, higher injury severity score (ISS), tracheostomy, diabetes, and so on \[[@CR8]--[@CR12]\]. However, these studies did not provide consistent evidence for prevention and treatment due to many reasons, such as small sample sizes, different population sources, and the use of different study designs \[[@CR11], [@CR12]\]. What is more, some studies indicated that VAP increased the risk of mortality \[[@CR13], [@CR14]\], but other studies showed that VAP was not associated with mortality \[[@CR9], [@CR15]\]. Identification of risk factors and outcomes associated with VAP could permit clinical staff to provide close infection surveillance and timely care for TBI patients at high risk for pneumonia. Therefore, a systematic summary is urgently needed.

In the present study, we performed a meta-analysis of the incidence, risk factors, and outcomes of VAP in patients with TBI, so as to provide evidence for the prevention and treatment of VAP among patients with TBI.

Methods {#Sec2}
=======

Search Strategy {#Sec3}
---------------

A literature search was performed using PubMed, EMBASE, Cochrane Library, and Web of Science databases up to May 2018. We used Medical Subject Headings and keywords as follows: (traumatic brain injury OR brain injuries, traumatic OR brain injury OR TBI OR craniocerebral trauma OR craniocerebral injury OR head injury OR head trauma) AND (ventilator-associated pneumonia OR VAP OR pneumonia, ventilator associated OR ventilator associated pneumonia). The specific searching strategy is described in Table S1. In the initial selection phase, two reviewers (Y.L. and C.L.) screened the title and abstract of studies independently. Studies that obviously did not meet the inclusion criteria were excluded, and those included articles were read in full text to confirm their eligibility. Any disagreement was resolved by discussion with a third reviewer (S.W.). Reference lists of relevant studies were also manually searched for further studies. The publication language of studies was not limited. Our search strategy was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines \[[@CR16]\], The PRISMA checklist is described in Table S2.

Inclusion Criteria {#Sec4}
------------------

The inclusion criteria for our study were: (1) All enrolled patients had undergone TBI and had mechanical ventilation for more than 48 h. (2) A clear definition and diagnosis of VAP. (3) Articles must provide one or more index for the incidence, risk factors, or outcomes of VAP. (4) Cohort study or case--control study. (5) Full text available. (6) When multiple publications contain duplicate results, the study with the largest population was included.

Data Extraction and Data Transformation {#Sec5}
---------------------------------------

Two people extract data from eligible articles independently, including study characteristics (first author, publication time, country, number of patients, number of VAP, gender, age, study design, the definition of VAP, the severity of TBI), incidence, risk factors, and indexes representing clinical outcomes (mortality, mechanical ventilation time, intensive care unit (ICU) length of stay, hospital length of stay), so as to provide a comprehensive description of VAP among patients with TBI.

Some studies were presenting continuous data (ventilator days, ICU length of stay, hospital length of stay, ISS \[[@CR17]\]) using the mean and standard deviation or using the median and the first and third quartiles. To be able to use these data in our meta-analysis, we converted the median and the first and third quartiles to the mean and standard deviation using the method described by Wan et al. \[[@CR18]\].

Quality Assessment {#Sec6}
------------------

The quality of the studies was evaluated by two independent reviewers (Y.L. and C.L.) using the Newcastle--Ottawa Scale (NOS) \[[@CR19]\], which was used for cohort designs and case--control designs. The quality of the studies was evaluated based on three perspectives: selection (four items), comparability (one item), and exposure or outcome (three items). The NOS rating system with a score ranging from 0 to 9 stars. High-quality studies should reach seven stars or more, 4--6 stars are of medium quality, and less than four stars are of poor quality.

Statistical Analysis {#Sec7}
--------------------

The incidence of VAP among patients with TBI was calculated using Stata 12.0 (Stata Corp, College Station, TX); subgroup analyses in terms of study design, region, the definition of VAP, and the severity of TBI were also performed. Risk factors and outcomes of VAP in patients with TBI were analyzed using the Review Manager Software (RevMan5.3; Cochrane Collaboration, Oxford, UK). For measurement data, the weighted mean difference and 95% confidence intervals (CIs) were calculated to compare the mean difference. For count data, odds ratios (ORs) and 95% CIs were used. They were considered significantly associated with VAP when *P* \< 0.05. Heterogeneity was calculated using *I*^2^ statistic. Heterogeneity was considered to be present if *I*^2^ \> 50% and random effects models were used; otherwise, a fixed effects model was used. Publication bias was performed by Begg's and Egger's test using Stata 12.0 \[[@CR20], [@CR21]\]; a *p* value \> 0.05 indicating the lack of publication bias.

Results {#Sec8}
=======

Literature Search {#Sec9}
-----------------

A total of 974 records were identified from the databases (PubMed: 182, EMBASE: 255, Cochrane Library: 135, Web of Science 393) and manually searched. After duplicates were removed, 658 records were retained. After initial screening of article titles and abstracts, 620 records were excluded. Then, 38 records were retained for further screening, among which, there were four reviews and three case reports; four studies were not having a useful index for the description of VAP, and five studies were not cohort studies or case--control studies. Not all the patients enrolled in seven studies were with TBI. Finally, 15 articles were included in this meta-analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of the study selection process

Study Characteristics and Quality Assessment {#Sec10}
--------------------------------------------

A total of 15 articles were included in this meta-analysis. The characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. Six studies were cohort studies, and nine studies were case--control studies. According to the NOS, two articles got eight stars, five articles got seven stars, five articles got six stars, and three articles got five stars (Table [2](#Tab2){ref-type="table"}).Table 1Characteristics of the studies included in the meta-analysisStudyCountryNumber of patientsNumber of VAPGender (male/female)AgeThe severity of TBIVAPNon-VAPVAPNon-VAPSirvent \[[@CR22]\]Spain1002622/452/2237 ± 19\*^,a^Moderate-to-severe TBILeone \[[@CR10]\]France324120--------All TBIRincón-Ferrari \[[@CR9]\]Spain3107265/7--28 (20--39.75)^†^--Severe TBIBronchard \[[@CR23]\]France10955----34 ± 15\*^,a^All TBIKallel \[[@CR14]\]Tunisia24177----35.8 ± 14.9\*--All TBIZygun \[[@CR15]\]Canada1346049/1155/1936 ± 16\*40 ± 20\*Severe TBIWu \[[@CR24]\]China2205330/23--33.8 ± 19.07\*--Severe TBILepelletier \[[@CR25]\]France16165101/60^b^39.8 ± 11.1\*^,a^Severe TBIMarjanović \[[@CR26]\]Serbia723122/931/1040.97 ± 16.84\*50.51 ± 18.92\*Severe TBIMa \[[@CR12]\]China1624027/1386/3636.6 ± 10.3\*37.5 ± 11.8\*Severe TBIPlurad \[[@CR11]\]USA943327/642/1930.4 ± 21.1\*^,a^Severe TBIGuo \[[@CR13]\]China1375278/59^b^41 ± 18\*44 ± 19\*Severe TBIJovanovic \[[@CR8]\]Serbia1447356/1759/12----Severe TBIHamele \[[@CR27]\]USA1194229/1356/219 (6--13)^†^6 (1.5--13)^†^Moderate-to-severe TBIEsnault \[[@CR7]\]France17510690/1649/2036 (23--53)^†^39 (23--59)^†^Severe TBIStudyIncidence of VAPEOVAPLOVAPStudy designDefinition of VAP(Time/incidence)(Time/incidence)Sirvent \[[@CR22]\]--≤ 5 days/26%--Prospective/cohortClinical, radiographical, microbiological criteriaLeone \[[@CR10]\]37%----Prospective/case--controlClinical, radiographical, microbiological criteriaRincón-Ferrari \[[@CR9]\]23.2%≤ 4 days/9.7%\>  days/13.5%Prospective/case--controlCDC criteriaBronchard \[[@CR23]\]50.5%≤ 7 days/41.3%\> 7 days/9.2%Prospective/cohortClinical, radiographical, microbiological criteriaKallel \[[@CR14]\]31.9%----Retrospective/case--controlClinical, radiographical, microbiological criteriaZygun \[[@CR15]\]45%----Prospective/cohortCDC criteriaWu \[[@CR24]\]24%≤ 4 days/9.5%\> 4 days/14.5%Retrospective/case--controlClinical, radiographical, microbiological criteriaLepelletier \[[@CR25]\]40.4%≤ 4 days/21.1%\> 4 days/19.3%Retrospective/cohortAmerican thoracic societyMarjanović [@CR26]\]43%----Retrospective/case--controlClinical, radiographical, microbiological criteriaMa \[[@CR12]\]25%----Retrospective/case--controlAmerican thoracic societyPlurad \[[@CR11]\]35%≤ 3 days/16%\> 3 days/19%Retrospective/case--controlClinical, radiographical, microbiological criteriaGuo \[[@CR13]\]38%----Retrospective/case--controlChinese Respiratory SocietyJovanovic \[[@CR8]\]50%≤ 4 days/24%\> 4 days/26%Prospective/cohortClinical, radiographical, microbiological criteriaHamele \[[@CR27]\]36%----Retrospective/cohortCDC criteriaEsnault \[[@CR7]\]--≤ 7 days/60.6%--Retrospective/case--controlClinical, radiographical, microbiological criteria*CDC* Centers for Disease Control and Prevention, *EOVAP* early-onset ventilator-associated pneumonia, *LOVAP* late-onset ventilator-associated pneumonia, *TBI* traumatic brain injury, *VAP* ventilator-associated pneumonia\*Values are represented as the mean ± standard derivation; ^†^values are represented as the median (interquartile range); ^a^age distribution of patients in both groups (VAP and non-VAP); ^b^gender distribution of patients in both groups (VAP and non-VAP) Table 2Quality assessment of the studies using the Newcastle--Ottawa scaleStudySelectionComparabilityExposureTotal scoresIs case definition adequate?Representativeness of casesSelection of controlsDefinition of controlsComparability on the basis of designs or analysisAscertainment of exposureSame ascertainment method for cases and controlsNonresponse rate*Case--control studies*Leone \[[@CR10]\]★★★★★★★★8Rincón-Ferrari \[[@CR9]\]★★★★★★★★8Kallel \[[@CR14]\]★★★★★★★7Wu \[[@CR24]\]★★★★★5Marjanović \[[@CR26]\]★★★★★5Ma \[[@CR12]\]★★★★★★6Plurad \[[@CR11]\]★★★★★★6Guo \[[@CR13]\]★★★★★5Esnault \[[@CR7]\]★★★★★★6SelectionComparabilityOutcomeTotal scoresRepresentativeness of exposed cohortSelection of the nonexposed cohortAscertainment of exposureDemonstration that outcome was not present at start of studyComparability on the basis of design or analysisAssessment of outcomeWas follow-up long enough for outcomes to occur?Adequacy of follow-up of cohorts*Cohort studies*Sirvent \[[@CR22]\]★★★★★★★7Bronchard \[[@CR23]\]★★★★★★★7Zygun \[[@CR15]\]★★★★★★★7Lepelletier \[[@CR25]\]★★★★★★6Jovanovic \[[@CR8]\]★★★★★★★7Hamele \[[@CR27]\]★★★★★★6

Incidence {#Sec11}
---------

The pooled incidence of VAP was 36% (95% CI 31--41%) among patients with TBI, as shown in Fig. [2](#Fig2){ref-type="fig"}a. We performed a subgroup analysis by study design (prospective and retrospective) to explore its impact on VAP incidence (Fig. [2](#Fig2){ref-type="fig"}b); The forest plot illustrated that the incidence of VAP in prospective studies (41%) was relatively higher than their counterparts in retrospective studies (33%). Stratified analysis based on variation in the region was applied because of its potential effect on the incidence of VAP (Fig. [2](#Fig2){ref-type="fig"}c), and the results showed that the incidence of VAP in North America (39%) and Europe (40%) was relatively higher than Asia (28%). We also performed a subgroup analysis by definition of VAP (Fig. [2](#Fig2){ref-type="fig"}d), and the results showed the incidence of VAP in Centers for Disease Control (CDC) criteria \[[@CR28]\], American Thoracic Society criteria \[[@CR29]\], Chinese Respiratory Society criteria \[[@CR30]\] with 34%, 32%, 38%, respectively. Considering the impact of TBI severity on the incidence of VAP, we performed a subgroup analysis based on the severity of TBI (Fig. [2](#Fig2){ref-type="fig"}e), and the result showed that the incidences of VAP in severe TBI patients (defined according to the standards used in the original study, such as Glasgow coma score (GCS) ≤ 8, the presence of clinical or radiographic herniation, etc.) and all TBI patients were similar, with 35% and 39%, respectively. In addition to the overall incidence of VAP, some studies divided VAP into early-onset ventilator-associated pneumonia (EOVAP) and late-onset ventilator-associated pneumonia (LOVAP). The results showed that the incidences of EOVAP (occurring in the first 3--7 days of mechanical ventilation) and LOVAP (occurring after 3--7 days of mechanical ventilation) were 26% and 16%, respectively (Fig. [2](#Fig2){ref-type="fig"}f, g).Fig. 2**a** Incidence of VAP in patients with TBI (*CI* confidence interval, *ID* identification). **b** Incidence of VAP by subgroup analysis of study design (prospective and retrospective) (*CI* confidence interval, *ID* identification). **c** Incidence of VAP by subgroup analysis of the region (*CI* confidence interval, *ID* identification). **d** Incidence of VAP by subgroup analysis of the definition of VAP (*CI* confidence interval, *ID* identification). **e** Incidence of VAP by subgroup analysis of the severity of TBI (*CI* confidence interval, *ID* identification, *TBI* traumatic brain injury). **f** Incidence of EOVAP in patients with TBI (*CI* confidence interval, *ID* identification). **g** Incidence of LOVAP in patients with TBI (*CI* confidence interval, *ID* identification)

Risk Factors {#Sec12}
------------

There are 18 potential risk factors (reported in at least two studies) summarized in this meta-analysis. We found a significant relationship between VAP and the following risk factors: smoking, tracheostomy, blood transfusion on admission, barbiturate infusion, ISS, head abbreviated injury scale (AIS), as noted in Table [3](#Tab3){ref-type="table"}. The data demonstrated that smoking increased the risk for VAP among patients with TBI (OR 2.13; 95% CI 1.16--3.92; *P* \< 0.05)\*\*. Additionally patients with tracheostomy were more vulnerable to VAP (OR 9.55; 95% CI 3.24--28.17; *P* \< 0.05). What is more, blood transfusion on admission also increased the risk for VAP (OR 2.54; 95% CI 1.24--5.18; *P* \< 0.05). Additionally, barbiturate infusion increased the risk for VAP among patients with TBI (OR 3.52; 95% CI 1.68--7.40; *P* \< 0.05). After data integration of three studies, pooled results showed that patients with higher ISS were more likely to be diagnosed with VAP compared to those with lower ISS (OR 4.65; 95% CI 1.96--7.34; *P* \< 0.05). Moreover, patients with head AIS ≥ 3 were more vulnerable to VAP (OR 2.99; 95% CI 1.66--5.37; *P* \< 0.05). No significant differences were detected based on gender (male), age, diabetes, shock, prophylactic antibiotics, corticosteroids, abdomen AIS, thorax AIS, thorax trauma, spinal trauma, facial trauma, abdomen trauma; therefore, these factors were determined not to be risk factors for VAP. The forest plots of risk factors are described in Figure S1.Table 3Risk factors of ventilator-associated pneumonia in patients with TBIRisk factorsCombination studiesAnalysis modelHeterogeneity of studies (*I*^2^) (%)Meta-analysisBegg's test (*p*)Egger's test (*p*)OR (95% CI)*P* valueGender (male)9Fixed01.02 (0.75--1.38)0.910.6020.304Age5Random65− 1.89 (− 5.57 to 1.80)0.320.0860.005Smoking2Fixed02.13 (1.16--3.92)0.011NAShock4Fixed251.27 (0.79--2.04)0.330.3080.531Diabetes3Fixed01.47 (0.72--3.01)0.3010.779Tracheostomy5Random859.55 (3.24--28.17)0.00110.675Blood transfusion on admission2Fixed22.54 (1.24--5.18)0.011NAProphylactic antibiotics3Random510.97 (0.50--1.90)0.930.2960.234Barbiturate infusion2Fixed03.52 (1.68--7.40)0.0011NACorticosteroids2Fixed01.47 (0.59--3.66)0.401NAISS3Fixed04.65 (1.96--7.34)0.00110.245AIS head ≥ 32Fixed02.99 (1.66--5.37)0.0011NAAIS abdomen ≥ 33Fixed241.32 (0.71--2.47)0.3810.452AIS thorax ≥ 34Random731.56 (0.65--3.76)0.3210.942Thorax trauma3Random822.04 (0.67--6.16)0.2110.794Spinal trauma2Random691.20 (0.30--4.77)0.801NAFacial trauma2Fixed00.83 (0.51--1.34)0.441NAAbdomen trauma2Random591.35 (0.45--4.07)0.591NA*AIS* abbreviated injury scale, *CI* confidence interval, *ISS* injury severity score, *NA* not available, *OR* odds ratio, *TBI* traumatic brain injury

Clinical Outcomes {#Sec13}
-----------------

After data integration of ten studies, pooled results showed that VAP was not associated with mortality (OR 1.28; 95% CI 0.74--2.21; *P* = 0.38), as shown in Fig. [3](#Fig3){ref-type="fig"}a. However, VAP increased the mechanical ventilation time (OR 5.45; 95% CI 3.78--7.12; *P*\<0.05), as shown in Fig. [3](#Fig3){ref-type="fig"}b. In addition, our pooled results also showed that ICU length of stay was increased significantly in patients infected with VAP (OR 6.85; 95% CI 4.90--8.79; *P*\<0.05), as shown in Fig. [3](#Fig3){ref-type="fig"}c. Patients who developed VAP also had a longer duration of hospital length of stay (OR 10.92; 95% CI 9.12--12.72; *P*\<0.05), as shown in Fig. [3](#Fig3){ref-type="fig"}d.Fig. 3Outcomes of VAP among patients with TBI. **a** Mortality; **b** mechanical ventilation time; **c** ICU length of stay; **d** hospital length of stay (*CI* confidence interval, *IV* inverse variance, *M--H* Mantel--Haenszel, *SD* standard deviation, *VAP* ventilator-associated pneumonia)

Publication Bias {#Sec14}
----------------

There was no significant publication bias in the analysis of the incidence of VAP by Egger's test (*P* = 0.196) and Begg's test (*P* = 0.161). The results of publication bias for risk factor analysis are shown in Table [3](#Tab3){ref-type="table"}. Moreover, the mortality (Egger's test *P* = 0.076; Begg's test *P* = 0.107), mechanical ventilation time (Egger's test *P* = 0.404; Begg's test *P* = 0.902), ICU length of stay (Egger's test *P* = 0.593; Begg's test *P* = 0.548), and hospital length of stay (Egger's test *P* = 0.454; Begg's test *P* = 0.296) also had no significant publication bias.

Discussion {#Sec15}
==========

To our best knowledge, this study was the first meta-analysis exploring the incidence, risk factors, and outcomes of VAP in patients with TBI.

This meta-analysis showed that the incidence of VAP in patients with TBI was 36% (95% CI 31--41%) by pooling data from the included studies. However, the spectacular disparity in the incidence of VAP was shown in the previous studies. Bronchard et al. \[[@CR23]\] and Jovanovic et al. \[[@CR8]\] reported that the incidence of VAP was 50%, while Rincón-Ferrari et al. \[[@CR9]\] found that the incidence of VAP was about 23%. Differences in the study design, region, definition of VAP, and the severity of TBI may explain this wide range, leading to subgroup analyses based on these factors. The result demonstrated that the incidence of VAP in prospective studies was significantly higher than retrospective studies (41% vs. 33%). A study performed by J Tobias et al. showed that data obtained retrospectively from the medical records were less complete and accurate compared to data obtained from the patients prospectively \[[@CR31]\]. Retrospective information is fraught with the problems of missing data, conflicting data, and illegibility \[[@CR32]\]. We recommend that more prospective studies be carried out in the future so as to obtain more rigorous results about VAP. In addition, there was a significant difference in the incidence of VAP between North America, Europe and Asia (39% vs. 40% vs. 28%) by subgroup analysis; this difference may be due to the lack of active infection monitoring systems in Asian countries compared to European and North American countries, which led to the inadequate feedback of hospital infection surveillance data and underestimate of the incidence of VAP \[[@CR33]--[@CR35]\]. What is more, the result showed that the incidences of VAP in severe TBI patients and all TBI patients were similar, with 35% and 39%, respectively. In this meta-analysis, three studies included all TBI patients, rather than only those with severe TBI \[[@CR10], [@CR14], [@CR23]\]. Most of the patients in these three studies had severe neurologic injury. The mean GCS score of patients was 7.38 in the study conducted by Kallel et al. \[[@CR14]\], and 7.2 in the study conducted by Bronchard et al. \[[@CR23]\]. The median GCS score of patients was 6 in the study conducted by Leone et al. \[[@CR10]\]. This may explain why the incidence of VAP in these three studies is similar to the studies including patients with severe TBI. Additionally, as for EOVAP and LOVAP, the incidence of EOVAP and LOVAP is related to the cutoff point used for definition \[[@CR36]\]. However, the cutoff point in the literature is usually inconsistent \[[@CR37]\]. Unifying EOVAP and LOVAP cutoff point is of great significance to the treatment of patients and clinical research. Further research is needed to accurately assess the cutoff point.

Identification of risk factors associated with VAP could permit clinical staff to provide close infection surveillance and timely care for TBI patients at high risk for pneumonia so as to optimize clinical outcomes. In the present meta-analysis, we integrated all eligible studies of VAP in patients with TBI. By integrating the results of previous studies and expanding the sample size, we found a significant relationship between VAP and the following risk factors: smoking, tracheostomy, blood transfusion on admission, barbiturate infusion, ISS, and head AIS. We identified that smoking increased the risk for VAP, probably because smoking impairs mucociliary clearance, making it easier for pathogens to colonize in the respiratory tract \[[@CR38]\]. Smoking remains an important contributor to pneumonia, and all patients with TBI should be encouraged to quit. Additionally, tracheotomy increased the risk for VAP; tracheotomy bypasses normal respiratory defense mechanisms, such as oropharynx and cilia, which contribute to the occurrence of VAP \[[@CR39]\]. It has been reported that use of suction-above-the-cuff tracheotomy tubes reduces the incidence of VAP \[[@CR40]\]. More attention in the details of tracheotomy care such as the use of suction-above-the-cuff tracheotomy tubes \[[@CR40]\] may be helpful in decreasing the associated risk when tracheotomy is performed. Furthermore, blood transfusion on admission heightens the risk for VAP, which may be because the early period of acute severe trauma is associated with an immunosuppressive inflammatory response, and this response was increased in magnitude when patients received a transfusion of blood products \[[@CR41], [@CR42]\]. In addition, our results showed that barbiturate use increased the risk of VAP in TBI patients, which may be related to the immunosuppressive effect of barbiturates given they; promote reversible bone marrow suppression in patients with TBI \[[@CR43]\] and increased susceptibility to develop VAP \[[@CR27]\]. Although some treatments such as the use of barbiturates or blood transfusions are frequently indicated, they should be administered appropriately. Moreover, the result of this meta-analysis demonstrated that patients with higher ISS or head AIS represent a specific target population for the prevention of VAP. The AIS provides a method for ranking and comparing injuries by severity in body regions \[[@CR44]\]. The ISS is derived from the AIS and provides a description of the overall severity of injury for patients with trauma \[[@CR17]\]. A study by Teixeira Lopes et al. \[[@CR45]\] analyzed the risk factors associated with post-traumatic complications in hospitalized trauma patients. The study revealed that the higher the severity of trauma, the greater the number of hospitalization complications. Furthermore, the main complications presented by trauma patients were infections, especially VAP and sepsis \[[@CR45], [@CR46]\]. The results suggest that ISS and AIS should be considered in therapeutic decisions to help healthcare providers properly identify patients at high risk for VAP and modify patient care to minimize the risk of VAP. VAP should be closely monitored to detect infections in the target population early and to take measures to achieve optimal results.

There is much discussion about whether to use prophylactic antibiotics for TBI patients. Our meta-analysis showed that there was no association between prophylactic antibiotics and the occurrence of VAP. A study by Reizine et al. \[[@CR47]\] showed that prophylactic antibiotics decreased the incidence of EOVAP but had no influence on LOVAP; additionally, they found that prophylactic antibiotics delayed the occurrence of VAP. Nevertheless, they suggested that antibiotic prophylaxis should not be routinely used in clinical practice because antibiotic prophylaxis has no effect on length of stay and mortality. In addition, a study by Hoth et al. \[[@CR48]\] showed that trauma patients receiving antibiotic prophylaxis showed an increase in multi-drug-resistant bacteria. For the reasons mentioned above, we do not recommend prophylactic antibiotics in patients with TBI.

The main finding of this study was that VAP did not increase the mortality in patients with TBI. This was consistent with the results of Bregeon's \[[@CR49]\] study, which ultimately showed that VAP did not seem to be an independent risk factor for death. Josephson's \[[@CR50]\] study also showed that VAP does not lead to increased mortality in patients with neurovascular diseases, and he pointed out that death in patients with VAP was due mainly to neurologic injury and withdrawal of care. Additionally, VAP increased the mechanical ventilation time and prolonged the ICU length of stay and hospital length of stay. This is in agreement with the findings of many studies \[[@CR51], [@CR52]\], indicating that VAP imposed a great burden on patients \[[@CR52]\].

This meta-analysis has many advantages. First of all, we conducted a systematic literature search. By integrating the results of previous studies, expanding the sample size and performing quantitative analysis, the accurate incidence of VAP in patients with TBI was provided from a global perspective. At the same time, subgroup analyses were performed to identify potential factors responsible for inconsistencies in previous studies, and we found that the incidence of VAP in North America (39%) and Europe (40%) was relatively higher than Asia (28%) and the incidence of VAP in prospective studies (41%) was relatively higher than that in retrospective studies (33%). In addition, we analyzed many aspects of VAP in patients with TBI including the incidence, risk factors, and outcomes so as to provide a comprehensive understanding of VAP.

Limitation {#Sec16}
----------

However, some limitations of this meta-analysis should be mentioned. First, the criteria used to diagnose VAP in the included studies were inconsistent and the analyzed studies used the following methods for VAP ascertainment: Three studies used the CDC criteria \[[@CR28]\], two studies used the American Thoracic Society criteria \[[@CR29]\], one study used the Chinese Respiratory Society criteria \[[@CR30]\], nine studies were based on clinical, radiographical and microbiological criteria to provide references for doctors' diagnosis. In addition, the cutoff points used to define EOVAP and LOVAP in the included studies were inconsistent. For example, some studies defined that VAP occurring in the first 4 days after mechanical ventilation was EOVAP \[[@CR9]\], while some studies defined that VAP occurring in the first 7 days after mechanical ventilation was EOVAP \[[@CR23]\]. We recommend that more research about EOVAP and LOVAP be conducted in the future, so as to get more accurate knowledge about it. There are still many uncertainties in the diagnosis of VAP, which needs further research.

Conclusions {#Sec17}
===========

In the present study, we integrated all eligible studies of VAP in patients with TBI, demonstrating that patients with TBI were at very high risk of developing VAP, with a pooled incidence of 36%. We also found that VAP does not increase the mortality in patients with TBI, but VAP increases the mechanical ventilation time, ICU length of stay, and hospital length of stay. Moreover, this meta-analysis demonstrated that smoking, tracheostomy, blood transfusion on admission, barbiturate infusion, ISS, and head AIS are risk factors for VAP, providing specific target population for the prevention of VAP.
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